Investigational drug · Phase 2
Bimagrumab
Also called: LY3985863, BYM338, VER201
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
18
Any phase or sponsor naming "Bimagrumab"
First trial start
2024
Oct 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bimagrumab", any sponsor or status.
- Phase 216
Conditions studied
As listed on its trial records.
- Heart Failure, Diastolic
- Diastolic Heart Failure
- Heart Failure, Normal Ejection Fraction
- Heart Failure, Preserved Ejection Fraction
- Obesity
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Bimagrumab" as an intervention, largest first.
- A Study of Bimagrumab in Participants With HFpEFPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07920887 · 540 participants (planned) · Start Nov 2026 · Primary completion Jul 2029
Drug: Bimagrumab; Placebo · For: Heart Failure, Diastolic; Diastolic Heart Failure; Heart Failure, Normal Ejection Fraction and 1 more
Sites: Van Nuys, California; North Miami Beach, Florida; Dallas, Texas · 9 sites in all
- Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObesePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05616013 · 507 participants · Start Nov 16, 2022 · Primary completion May 16, 2024
Drug: Bimagrumab; Semaglutide · For: Obesity; Obese; Overweight or Obesity
Sites: Anniston, Alabama; Cullman, Alabama; Hialeah, Florida · 26 sites in all
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06643728 · 252 participants · Start Oct 21, 2024 · Primary completion Jan 16, 2026
Drug: Bimagrumab; Tirzepatide and 2 more · For: Obesity; Overweight
Sites: Anniston, Alabama; Birmingham, Alabama; Walnut Creek, California · 12 sites in all
- Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture SurgeryPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02152761 · 251 participants · Start Sep 16, 2014 · Primary completion May 14, 2018
Drug: bimagrumab · For: Muscle Wasting (Atrophy) After Hip Fracture Surgery
Sites: Phoenix, Arizona; El Cajon, California; Denver, Colorado · 53 sites in all
- Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01925209 · 251 participants · Start Sep 26, 2013 · Primary completion Jan 6, 2016
Drug: BYM338/bimagrumab; Placebo · For: Sporadic Inclusion Body Myositis
Sites: Phoenix, Arizona; Orange, California; Sacramento, California · 38 sites in all
- Dose Range Finding Study of Bimagrumab in SarcopeniaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02333331 · 217 participants · Start Dec 9, 2014 · Primary completion Jun 26, 2018
Drug: bimagrumab · For: Sarcopenia
Sites: Little Rock, Arkansas; Cypress, California; La Jolla, California · 58 sites in all
- An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02573467 · 211 participants · Start Nov 2, 2015 · Primary completion Aug 17, 2016
Drug: Bimagrumab; Placebo · For: Sporadic Inclusion Body Myositis
Sites: Phoenix, Arizona; Orange, California; Sacramento, California · 38 sites in all
- A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core StudyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02468674 · 160 participants · Start Jul 22, 2015 · Primary completion Dec 3, 2018
Drug: bimagrumab; Placebo · For: Sarcopenia
Sites: Miami Lakes, Florida; Gainesville, Georgia; Spartanburg, South Carolina · 30 sites in all
- A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06890611 · 125 participants · Start Mar 25, 2025 · Primary completion Sep 26, 2025
Drug: Bimagrumab; Tirzepatide and 1 more · For: Healthy
Sites: Dallas, Texas
Novartis PharmaceuticalsNovartis (NVS)
NCT03005288 · 78 participants · Start Feb 1, 2017 · Primary completion Mar 21, 2019
Drug: BYM338 10 mg/kg · For: Diabetes Mellitus, Type 2
Sites: Anaheim, California; Miami, Florida; Miami Lakes, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy.
Baka T, Mirrione SM, Qin F, et al. · J Cachexia Sarcopenia Muscle 2026
- Integrative transcriptomics identifies an 18-gene candidate blood-accessible biomarker panel for longitudinal monitoring of spaceflight-induced muscle atrophy.
Shim JH, Lee JY, Han J, et al. · PLoS One 2026
- Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Shao C, Lin H, Yu J, et al. · Diabetes Obes Metab 2026
- GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytes.
Kotikalapudi N, Ramachandran D, Zhou EY, et al. · bioRxiv 2026
- Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.
Rooks D, Yates DP, Neelakantham S, et al. · J Clin Endocrinol Metab 2026
- Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.
Sanghvi MM, Nicholls HL, Kaplan TM, et al. · J Am Coll Cardiol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.